PR
Corestem is a biopharmaceutical company that researches and commercializes stem cell technology.
Press Report
-
2022.07.07Corestem Shares Protocol for L..Corestem Shares Protocol for Long-term NeuroNata-R TrialbyMa..
-
2021.04.19Does CORESTEM (KOSDAQ:166480) ..Does CORESTEM (KOSDAQ:166480) Have A Healthy Balance Sheet?B..
-
2021.04.07Explore ALS Trials – ALS Signa..Explore ALS Trials – ALS Signal: Clinical Research Dashboard..
-
2021.04.07Phase 3 Trial of Stem Cell The..Phase 3 Trial of Stem Cell Therapy NeuroNata-R Enrolling in ..
-
2020.11.02Study links two ALS mechanismsStudy links two ALS mechanismsByJohn FoxNovember 2, 2020Muta..
-
2020.06.03KIM, Kyung Sook CEO Interview..Kyung Sook Kim – CEO, Corestem, South KoreaDr Kyung Sook Kim..
- 24, Pangyo-ro 255beon-gil, Bundang-gu, Seongnam-si, Gyeonggi-do, Korea
- Gen (02) 497-3711
- IR DID 070-4706-3546
- FAX (02) 6349-8666
- E-MAIL corestem@corestem.com
Copyright 2018 CORESTEM, Inc All right reserved.
